Exploring the Current Applications and Challenges of Targeted Liposomal Drug Delivery

Najahi Gatto^*
*Correspondence: Najahi Gatto, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA, Email:

Introduction

Liposomal drug delivery systems have emerged as one of the most innovative and effective methods for enhancing the therapeutic potential of drugs. The unique ability of liposomes—spherical vesicles composed of lipid bilayers—to encapsulate both hydrophilic and hydrophobic substances has made them invaluable in the field of drug delivery. Moreover, when modified for targeted delivery, liposomes can improve drug specificity, reduce side effects, and enhance bioavailability, particularly in the treatment of complex diseases such as cancer and infectious diseases. Targeted liposomal drug delivery refers to the modification of liposomes to direct the release of drugs to specific tissues or cells, thereby increasing the therapeutic efficacy and minimizing harmful side effects on healthy tissues. Despite the promising potential of targeted liposomal systems, their clinical translation faces several challenges. This article provides an overview of the current applications of targeted liposomal drug delivery and explores the key challenges that need to be addressed for their optimal use in medical practice. Targeted liposomal drug delivery systems have shown great promise in various therapeutic areas. By modifying liposomes with targeting ligands, such as antibodies, peptides, or aptamers, drugs can be delivered directly to the disease site, minimizing the need for high drug doses and reducing the risk of off-target effects [1-3]

Description

One of the most well-established applications of targeted liposomal drug delivery is in cancer therapy. Cancer cells often have unique surface markers that differ from normal cells, providing an opportunity to design liposomes that target these markers. Traditional chemotherapy treatments often involve the systemic administration of drugs that are toxic to both cancerous and healthy cells, leading to severe side effects. Liposomal formulations of chemotherapy agents, such as doxorubicin, encapsulated in liposomes, have been developed to reduce these adverse effects. By modifying liposomes with antibodies or ligands that specifically bind to receptors overexpressed on cancer cells, the drugs can be delivered more selectively to tumor tissues, thus enhancing the therapeutic effect while sparing healthy cells. Gene therapy involves the delivery of genetic material, such as DNA or RNA, to cells for therapeutic purposes. Liposomes have been extensively studied as vectors for gene delivery due to their ability to protect the genetic material from degradation and facilitate its uptake by target cells. Targeted liposomal delivery systems are particularly important in gene therapy, as they allow for more precise delivery to specific cells or tissues, improving the efficacy and safety of the therapy. For instance, liposomes modified with ligands that target cell surface receptors can enhance the delivery of plasmid DNA or small interfering RNA to specific cells, such as cancer cells or cells with genetic mutations [4,5].

Conclusion

Targeted liposomal drug delivery systems represent a promising strategy to improve the therapeutic index of many drugs by directing them to specific sites in the body, thereby enhancing efficacy while minimizing side effects. From cancer therapies to gene delivery and infectious disease treatments, targeted liposomal formulations have the potential to revolutionize modern medicine. However, challenges related to formulation, targeting efficiency, immunogenicity, and regulatory approval remain significant barriers to their widespread use. Continued research and development in these areas will be crucial in overcoming these obstacles and unlocking the full potential of targeted liposomal drug delivery.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Cattell, Raymond B. "The scree test for the number of factors." Multivariate Behav Res 1 (1966): 245-276.

Google Scholar, Crossref, Indexed at

2. Labenz, Christian, Anita Arslanow, Marc Nguyen-Tat and Michael Nagel, et al. "Structured early detection of asymptomatic liver cirrhosis: Results of the population-based liver screening program SEAL." J Hepatol 77 (2022): 695-701.

Google Scholar, Crossref, Indexed at

3. Reddy, O. Sreekanth, M. C. S. Subha, T. Jithendra and C. Madhavi, et al. "Curcumin encapsulated dual cross linked sodium alginate/montmorillonite polymeric composite beads for controlled drug delivery." Int J Pharm Sci Res 11 (2021): 191-199.

Google Scholar, Crossref, Indexed at

4. Azad, Abul Kalam, Sinan Mohammed Abdullah Al-Mahmood, John F. Kennedy and Bappaditya Chatterjee, et al. "Electro-hydrodynamic assisted synthesis of lecithin-stabilized peppermint oil-loaded alginate microbeads for intestinal drug delivery." Int J Biol Macromol 185 (2021): 861-875.

Google Scholar, Crossref, Indexed at

5. Mollah, M. Z. I., H. M. Zahid, Z. Mahal and Mohammad Rashed Iqbal Faruque, et al. "The usages and potential uses of alginate for healthcare applications." Front Mol Biosci 8 (2021): 719972.

Google Scholar, Crossref, Indexed at